Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
The American College of Rheumatology (ACR) and the American College of Hip Surgery (AAHKS) have released new guidelines.
Read Full NewsDefinium Therapeutics said on Monday its LSD-based treatment reduced symptoms of generalized anxiety disorder in a second successful late-stage study for the...
For patients with small-cell lung cancer, skipping preventive cranial radiotherapy in favor of MRI monitoring may improve outcomes.
1.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
2.
High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment
3.
Atezolizumab + Cabozantinib Postpones mCRPC Progression.
4.
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
5.
Checking PSA levels too soon after prostate cancer surgery can lead to overtreatment, study suggests
1.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
2.
Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics
3.
Proteogenomic Classification of Myeloid Disorders: Integrating Molecular Profiles for Precision Medicine
4.
Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management
5.
Breaking Barriers in Cancer Treatment: The Role of Innovative Oncology Drugs
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
5.
Efficient Management of First line ALK-rearranged NSCLC - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge